Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy, Biologic therapy.

The Royal Marsden Hospital, Surrey, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:Surrey
Treatments:Chemotherapy, Biologic therapyHospital:The Royal Marsden Hospital
Drugs:Journal:Link
Date:Sep 2012

Description:

Patients:
This phase II study involved 74 women with previously treated ovarian cancer. The median age was 58.1 years.

Treatment:
Patients were treated with a combination of the chemotherapy agents carboplatin and either paclitaxel or gemcitabine. They were also treated with the biologic therapy agent called pertuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor that works to interfere with tumor growth.

Toxicities:
There was one treatment-related death due to an unspecified cause. Grade 3-4 neutropenia, thrombocytopenia, diarrhea, and fatigue were also reported.

Results:
The median overall survival was 28.2 months.

Support:
This study was funded by the pharmaceutical company F. Hoffmann-La Roche.

Correspondence: Dr. S. B. Kaye; email: [email protected]



Back